NVCHI
PTGX icon

New Vernon Capital Holdings II’s Protagonist Therapeutics PTGX Stock Holding History

New Vernon Capital Holdings II’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,137
Closed -$361K – 96
2025
Q4 		$361K Sell
4,137
-3,061
-43% -$251K 0.17% 33
2025
Q3 		$478K Hold
7,198
– – 0.22% 31
2025
Q2 		$398K Sell
7,198
-340,897
-98% -$16.4M 0.19% 31
2025
Q1 		$7.2M Buy
348,095
+345,034
+11,272% +$14.5M 0.16% 40
2024
Q4 		$118K Buy
+3,061
New +$133K 0.08% 63

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

New Vernon Capital Holdings II's PTGX Position: Q1 2026 in Review

New Vernon Capital Holdings II sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 4,137 shares — an estimated $361K sold.

New Vernon Capital Holdings II first reported a position in PTGX in Q4 2024 and held it in 5 quarters. The position peaked at $7.2M in Q1 2025. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • New Vernon Capital Holdings II reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • New Vernon Capital Holdings II sold 4,137 Protagonist Therapeutics shares in Q1 2026, an estimated $361K.
  • New Vernon Capital Holdings II first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 5 quarters.
  • New Vernon Capital Holdings II's Protagonist Therapeutics position peaked at $7.2M in Q1 2025.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on New Vernon Capital Holdings II's 13F filing for Q1 2026, filed 15 May 2026.